607 related articles for article (PubMed ID: 33271067)
41. Molecular dynamic simulation analysis of SARS-CoV-2 spike mutations and evaluation of ACE2 from pets and wild animals for infection risk.
Chen P; Wang J; Xu X; Li Y; Zhu Y; Li X; Li M; Hao P
Comput Biol Chem; 2022 Feb; 96():107613. PubMed ID: 34896769
[TBL] [Abstract][Full Text] [Related]
42. Interactions of angiotensin-converting enzyme-2 (ACE2) and SARS-CoV-2 spike receptor-binding domain (RBD): a structural perspective.
Borkotoky S; Dey D; Hazarika Z
Mol Biol Rep; 2023 Mar; 50(3):2713-2721. PubMed ID: 36562937
[TBL] [Abstract][Full Text] [Related]
43. SARS-CoV-2 Omicron variant: Antibody evasion and cryo-EM structure of spike protein-ACE2 complex.
Mannar D; Saville JW; Zhu X; Srivastava SS; Berezuk AM; Tuttle KS; Marquez AC; Sekirov I; Subramaniam S
Science; 2022 Feb; 375(6582):760-764. PubMed ID: 35050643
[TBL] [Abstract][Full Text] [Related]
44. Comprehensive deep mutational scanning reveals the pH induced stability and binding differences between SARS-CoV-2 spike RBD and human ACE2.
Haque S; Mathkor DM; Alkhanani MF; Bantun F; Momenah AM; Faidah H; Jalal NA; Kumar V
J Biomol Struct Dyn; 2023; 41(24):15207-15218. PubMed ID: 36995177
[TBL] [Abstract][Full Text] [Related]
45. Receptor binding and complex structures of human ACE2 to spike RBD from omicron and delta SARS-CoV-2.
Han P; Li L; Liu S; Wang Q; Zhang D; Xu Z; Han P; Li X; Peng Q; Su C; Huang B; Li D; Zhang R; Tian M; Fu L; Gao Y; Zhao X; Liu K; Qi J; Gao GF; Wang P
Cell; 2022 Feb; 185(4):630-640.e10. PubMed ID: 35093192
[TBL] [Abstract][Full Text] [Related]
46. In silico binding profile characterization of SARS-CoV-2 spike protein and its mutants bound to human ACE2 receptor.
Zhang Y; He X; Zhai J; Ji B; Man VH; Wang J
Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34013346
[TBL] [Abstract][Full Text] [Related]
47. Omicron SARS-CoV-2 mutations stabilize spike up-RBD conformation and lead to a non-RBM-binding monoclonal antibody escape.
Zhao Z; Zhou J; Tian M; Huang M; Liu S; Xie Y; Han P; Bai C; Han P; Zheng A; Fu L; Gao Y; Peng Q; Li Y; Chai Y; Zhang Z; Zhao X; Song H; Qi J; Wang Q; Wang P; Gao GF
Nat Commun; 2022 Aug; 13(1):4958. PubMed ID: 36002453
[TBL] [Abstract][Full Text] [Related]
48. Structural basis for SARS-CoV-2 Delta variant recognition of ACE2 receptor and broadly neutralizing antibodies.
Wang Y; Liu C; Zhang C; Wang Y; Hong Q; Xu S; Li Z; Yang Y; Huang Z; Cong Y
Nat Commun; 2022 Feb; 13(1):871. PubMed ID: 35169135
[TBL] [Abstract][Full Text] [Related]
49. Functional and genetic analysis of viral receptor ACE2 orthologs reveals a broad potential host range of SARS-CoV-2.
Liu Y; Hu G; Wang Y; Ren W; Zhao X; Ji F; Zhu Y; Feng F; Gong M; Ju X; Zhu Y; Cai X; Lan J; Guo J; Xie M; Dong L; Zhu Z; Na J; Wu J; Lan X; Xie Y; Wang X; Yuan Z; Zhang R; Ding Q
Proc Natl Acad Sci U S A; 2021 Mar; 118(12):. PubMed ID: 33658332
[TBL] [Abstract][Full Text] [Related]
50. Structural basis of receptor recognition by SARS-CoV-2.
Shang J; Ye G; Shi K; Wan Y; Luo C; Aihara H; Geng Q; Auerbach A; Li F
Nature; 2020 May; 581(7807):221-224. PubMed ID: 32225175
[TBL] [Abstract][Full Text] [Related]
51. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies.
Yi C; Sun X; Ye J; Ding L; Liu M; Yang Z; Lu X; Zhang Y; Ma L; Gu W; Qu A; Xu J; Shi Z; Ling Z; Sun B
Cell Mol Immunol; 2020 Jun; 17(6):621-630. PubMed ID: 32415260
[TBL] [Abstract][Full Text] [Related]
52. Interaction of the spike protein RBD from SARS-CoV-2 with ACE2: Similarity with SARS-CoV, hot-spot analysis and effect of the receptor polymorphism.
Othman H; Bouslama Z; Brandenburg JT; da Rocha J; Hamdi Y; Ghedira K; Srairi-Abid N; Hazelhurst S
Biochem Biophys Res Commun; 2020 Jun; 527(3):702-708. PubMed ID: 32410735
[TBL] [Abstract][Full Text] [Related]
53. Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2.
Huang KA; Zhou D; Tan TK; Chen C; Duyvesteyn HME; Zhao Y; Ginn HM; Qin L; Rijal P; Schimanski L; Donat R; Harding A; Gilbert-Jaramillo J; James W; Tree JA; Buttigieg K; Carroll M; Charlton S; Lien CE; Lin MY; Chen CP; Cheng SH; Chen X; Lin TY; Fry EE; Ren J; Ma C; Townsend AR; Stuart DI
Theranostics; 2022; 12(1):1-17. PubMed ID: 34987630
[No Abstract] [Full Text] [Related]
54. Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2.
Song W; Gui M; Wang X; Xiang Y
PLoS Pathog; 2018 Aug; 14(8):e1007236. PubMed ID: 30102747
[TBL] [Abstract][Full Text] [Related]
55. Real-Time Conformational Dynamics of SARS-CoV-2 Spikes on Virus Particles.
Lu M; Uchil PD; Li W; Zheng D; Terry DS; Gorman J; Shi W; Zhang B; Zhou T; Ding S; Gasser R; Prévost J; Beaudoin-Bussières G; Anand SP; Laumaea A; Grover JR; Liu L; Ho DD; Mascola JR; Finzi A; Kwong PD; Blanchard SC; Mothes W
Cell Host Microbe; 2020 Dec; 28(6):880-891.e8. PubMed ID: 33242391
[TBL] [Abstract][Full Text] [Related]
56. Silico analysis of interaction between full-length SARS-CoV2 S protein with human Ace2 receptor: Modelling, docking, MD simulation.
Rui L; Haonan L; Wanyi C
Biophys Chem; 2020 Dec; 267():106472. PubMed ID: 32916377
[TBL] [Abstract][Full Text] [Related]
57. Protein structure analysis of the interactions between SARS-CoV-2 spike protein and the human ACE2 receptor: from conformational changes to novel neutralizing antibodies.
Mercurio I; Tragni V; Busto F; De Grassi A; Pierri CL
Cell Mol Life Sci; 2021 Feb; 78(4):1501-1522. PubMed ID: 32623480
[TBL] [Abstract][Full Text] [Related]
58. An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction.
Hanke L; Vidakovics Perez L; Sheward DJ; Das H; Schulte T; Moliner-Morro A; Corcoran M; Achour A; Karlsson Hedestam GB; Hällberg BM; Murrell B; McInerney GM
Nat Commun; 2020 Sep; 11(1):4420. PubMed ID: 32887876
[TBL] [Abstract][Full Text] [Related]
59. Strategies to target SARS-CoV-2 entry and infection using dual mechanisms of inhibition by acidification inhibitors.
Prabhakara C; Godbole R; Sil P; Jahnavi S; Gulzar SE; van Zanten TS; Sheth D; Subhash N; Chandra A; Shivaraj A; Panikulam P; U I; Nuthakki VK; Puthiyapurayil TP; Ahmed R; Najar AH; Lingamallu SM; Das S; Mahajan B; Vemula P; Bharate SB; Singh PP; Vishwakarma R; Guha A; Sundaramurthy V; Mayor S
PLoS Pathog; 2021 Jul; 17(7):e1009706. PubMed ID: 34252168
[TBL] [Abstract][Full Text] [Related]
60. Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies.
Jette CA; Cohen AA; Gnanapragasam PNP; Muecksch F; Lee YE; Huey-Tubman KE; Schmidt F; Hatziioannou T; Bieniasz PD; Nussenzweig MC; West AP; Keeffe JR; Bjorkman PJ; Barnes CO
Cell Rep; 2021 Sep; 36(13):109760. PubMed ID: 34534459
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
